Publication

Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus

Dolff, S., Abdulahad, W. H., Westra, J., Doornbos-van der Meer, B., Limburg, P. C., Kallenberg, C. G. M. & Bijl, M., 29-Sep-2011, In : Arthritis Research and Therapy. 13, 5, 10 p., 157.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Dolff, S., Abdulahad, W. H., Westra, J., Doornbos-van der Meer, B., Limburg, P. C., Kallenberg, C. G. M., & Bijl, M. (2011). Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthritis Research and Therapy, 13(5), [157]. https://doi.org/10.1186/ar3474

Author

Dolff, Sebastian ; Abdulahad, Wayel H. ; Westra, Johanna ; Doornbos-van der Meer, Berber ; Limburg, Pieter C. ; Kallenberg, Cees G. M. ; Bijl, Marc. / Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. In: Arthritis Research and Therapy. 2011 ; Vol. 13, No. 5.

Harvard

Dolff, S, Abdulahad, WH, Westra, J, Doornbos-van der Meer, B, Limburg, PC, Kallenberg, CGM & Bijl, M 2011, 'Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus', Arthritis Research and Therapy, vol. 13, no. 5, 157. https://doi.org/10.1186/ar3474

Standard

Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. / Dolff, Sebastian; Abdulahad, Wayel H.; Westra, Johanna; Doornbos-van der Meer, Berber; Limburg, Pieter C.; Kallenberg, Cees G. M.; Bijl, Marc.

In: Arthritis Research and Therapy, Vol. 13, No. 5, 157, 29.09.2011.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Dolff S, Abdulahad WH, Westra J, Doornbos-van der Meer B, Limburg PC, Kallenberg CGM et al. Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthritis Research and Therapy. 2011 Sep 29;13(5). 157. https://doi.org/10.1186/ar3474


BibTeX

@article{9264a905af9548e6aa1e5f5af2a8169f,
title = "Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus",
abstract = "Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease accompanied by a disturbed T-cell balance skewed towards effector T-cells, in particular Th17-cells. The novel cytokine interleukin-21 (IL-21) is suggested to be crucial for triggering T-cell responses towards IL-17 producing cells. Thus, we aimed to investigate the ability of T-cells to produce IL-21 and IL-17 in SLE patients.Methods: Peripheral blood of 34 SLE patients and 18 healthy controls (HC) was stimulated with phorbol myristate acetate (PMA) and calcium ionophore (Ca-Io). Percentages of IL-21-and IL-17A expressing T-cells were analysed by flow cytometry. The expression levels of the transcription factors B-cell lymphoma-6 (BCL-6) and factors retinoid-related orphan receptor (ROR-gamma t) were assessed in T-cells by real-time RT-PCR and flow cytometry. Additionally, IL-21 receptor (IL-21R) expression on B-and T-cells of patients and HC was analyzed.Results: Significantly increased percentages of IL-21 expressing CD4(+) T-cells and CD8(+) T-cells were found in SLE patients as compared to HC. The percentages of IL-21(+) CD4(+) T-cells and CD8(+) T-cells correlated significantly with the percentages of IL-17A(+) CD4(+) T-cells and CD8(+) T-cells, respectively. The relative expression of BCL-6 and ROR-gamma t did not differ between SLE patients and HC. IL-21R expression occurred mainly on B-cells and was not different comparing SLE patients and HC.Conclusions: This study demonstrates an increased proportion of IL-21(+) T-cells in SLE patients correlating with the proportion of IL-17(+) T-cells. This suggests a pivotal role of IL-21 in the pathogenesis of SLE.",
keywords = "SLE, Th17-cells, IL-21, T-cells, DISEASE-ACTIVITY, RECEPTOR, INTERLEUKIN-21, EXPANSION, DIFFERENTIATION, AUTOIMMUNITY, INFLAMMATION, ACTIVATION, BLOCKADE, PATHWAY",
author = "Sebastian Dolff and Abdulahad, {Wayel H.} and Johanna Westra and {Doornbos-van der Meer}, Berber and Limburg, {Pieter C.} and Kallenberg, {Cees G. M.} and Marc Bijl",
year = "2011",
month = "9",
day = "29",
doi = "10.1186/ar3474",
language = "English",
volume = "13",
journal = "Arthritis Research and Therapy",
issn = "1478-6362",
publisher = "BioMed Central Ltd.",
number = "5",

}

RIS

TY - JOUR

T1 - Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus

AU - Dolff, Sebastian

AU - Abdulahad, Wayel H.

AU - Westra, Johanna

AU - Doornbos-van der Meer, Berber

AU - Limburg, Pieter C.

AU - Kallenberg, Cees G. M.

AU - Bijl, Marc

PY - 2011/9/29

Y1 - 2011/9/29

N2 - Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease accompanied by a disturbed T-cell balance skewed towards effector T-cells, in particular Th17-cells. The novel cytokine interleukin-21 (IL-21) is suggested to be crucial for triggering T-cell responses towards IL-17 producing cells. Thus, we aimed to investigate the ability of T-cells to produce IL-21 and IL-17 in SLE patients.Methods: Peripheral blood of 34 SLE patients and 18 healthy controls (HC) was stimulated with phorbol myristate acetate (PMA) and calcium ionophore (Ca-Io). Percentages of IL-21-and IL-17A expressing T-cells were analysed by flow cytometry. The expression levels of the transcription factors B-cell lymphoma-6 (BCL-6) and factors retinoid-related orphan receptor (ROR-gamma t) were assessed in T-cells by real-time RT-PCR and flow cytometry. Additionally, IL-21 receptor (IL-21R) expression on B-and T-cells of patients and HC was analyzed.Results: Significantly increased percentages of IL-21 expressing CD4(+) T-cells and CD8(+) T-cells were found in SLE patients as compared to HC. The percentages of IL-21(+) CD4(+) T-cells and CD8(+) T-cells correlated significantly with the percentages of IL-17A(+) CD4(+) T-cells and CD8(+) T-cells, respectively. The relative expression of BCL-6 and ROR-gamma t did not differ between SLE patients and HC. IL-21R expression occurred mainly on B-cells and was not different comparing SLE patients and HC.Conclusions: This study demonstrates an increased proportion of IL-21(+) T-cells in SLE patients correlating with the proportion of IL-17(+) T-cells. This suggests a pivotal role of IL-21 in the pathogenesis of SLE.

AB - Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease accompanied by a disturbed T-cell balance skewed towards effector T-cells, in particular Th17-cells. The novel cytokine interleukin-21 (IL-21) is suggested to be crucial for triggering T-cell responses towards IL-17 producing cells. Thus, we aimed to investigate the ability of T-cells to produce IL-21 and IL-17 in SLE patients.Methods: Peripheral blood of 34 SLE patients and 18 healthy controls (HC) was stimulated with phorbol myristate acetate (PMA) and calcium ionophore (Ca-Io). Percentages of IL-21-and IL-17A expressing T-cells were analysed by flow cytometry. The expression levels of the transcription factors B-cell lymphoma-6 (BCL-6) and factors retinoid-related orphan receptor (ROR-gamma t) were assessed in T-cells by real-time RT-PCR and flow cytometry. Additionally, IL-21 receptor (IL-21R) expression on B-and T-cells of patients and HC was analyzed.Results: Significantly increased percentages of IL-21 expressing CD4(+) T-cells and CD8(+) T-cells were found in SLE patients as compared to HC. The percentages of IL-21(+) CD4(+) T-cells and CD8(+) T-cells correlated significantly with the percentages of IL-17A(+) CD4(+) T-cells and CD8(+) T-cells, respectively. The relative expression of BCL-6 and ROR-gamma t did not differ between SLE patients and HC. IL-21R expression occurred mainly on B-cells and was not different comparing SLE patients and HC.Conclusions: This study demonstrates an increased proportion of IL-21(+) T-cells in SLE patients correlating with the proportion of IL-17(+) T-cells. This suggests a pivotal role of IL-21 in the pathogenesis of SLE.

KW - SLE

KW - Th17-cells

KW - IL-21

KW - T-cells

KW - DISEASE-ACTIVITY

KW - RECEPTOR

KW - INTERLEUKIN-21

KW - EXPANSION

KW - DIFFERENTIATION

KW - AUTOIMMUNITY

KW - INFLAMMATION

KW - ACTIVATION

KW - BLOCKADE

KW - PATHWAY

U2 - 10.1186/ar3474

DO - 10.1186/ar3474

M3 - Article

VL - 13

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6362

IS - 5

M1 - 157

ER -

ID: 5516258